CTT1403 / Cancer Targeted Tech - LARVOL DELTA

GU Oncologists Anticipate Earlier Role of Lutetium-177 PSMA-617 in Prostate Cancer (Targeted Oncology) - "In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer....When looking forward to a potential approval of radioligand therapy in the prechemotherapy setting, 'we need to do a better job educating our providers on which patient needs a PARP inhibitor [or] chemotherapy, and which is a good candidate to go on [177Lu-PSMA-617]...' said Benjamin Garmezy, MD...interview with Peers & Perspectives in Oncology....Garmezy said that in his experience, the first patients treated in real-world practice were essentially deciding between 177Lu-PSMA-617 and hospice, and this was not the ideal patient population to gauge the drug's performance. 'When [177Lu-PSMA-617] first got approved, there was a rush of patients who needed to get it because they were out of all other FDA-approved options for their cancer,' he explained.'"

Interview

Safety and effectiveness of Lutetium-177–Prostate-specific membrane antigen therapy in patients with Metastatic Castrate resistant prostate cancer and Prior Radium-223 therapy

Live event

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=17 | Completed | Sponsor: Cancer Targeted Technology | Active, not recruiting ➔ Completed | N=40 ➔ 17

Enrollment change • Metastases • Trial completion • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Cancer Targeted Technology | Trial completion date: Dec 2021 ➔ Jul 2022 | Trial primary completion date: Dec 2021 ➔ Jun 2022 | Recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Cancer Targeted Technology Receives Milestone Payment for Development of Diagnostic PET Imaging Agent for Prostate Cancer (Businesswire) - “Cancer Targeted Technology…received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, triggered by the upcoming clinical trials of investigational 18F-CTT1057, a diagnostic PET imaging agent for prostate cancer…Prior to licensing, CTT completed prostate cancer clinical trials of CTT1057 in adult males at University of California, San Francisco (UCSF), with encouraging safety and imaging results. Based on this clinical data, binding characteristics of the molecule, and solid patent protection, CTT1057 was licensed to AAA to undergo further development in the upcoming GuidePath and GuideView clinical studies…The milestone payments, along with an NIH SBIR Phase IIB grant, are the key assets that CTT is using to advance its new radiolabeled small molecule drug CTT1403, a companion radiotherapeutic to CTT1057.”

Licensing / partnership • Genito-urinary Cancer • Oncology • Prostate Cancer

NIH grants $1.44M to Cancer Targeted Technology to Support the Ongoing Prostate Cancer Clinical Trial of a Promising New Radiotherapeutic, CTT1403 (Businesswire) - "Cancer Targeted Technology...announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial...The trial is designed to show safety and efficacy of CTT1403 and is halfway through the initial dose escalation phase. To date there have been no safety issues with the drug and the pharmacokinetic data support the longer circulation time of CTT1403 in the blood stream as compared to other PSMA agents currently in clinical trials....CTT1057 is undergoing further development for prostate cancer by CTT’s licensing partner AAA/Novartis."

Clinical • Grant • Trial status • Genito-urinary Cancer • Oncology • Prostate Cancer

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Cancer Targeted Technology; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Cancer Targeted Technology; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403. (PubMed, Mol Imaging Biol) - "The preclinical efficacy and dosimetry of CTT1403 suggest that this agent has significant potential to be safe and effective in humans."

Biomarker • Journal • Preclinical

Cancer Targeted Technology commences phase I clinical trial in prostate cancer patients with an innovative radiotherapy, CTT1403, and receives a $3.2M NIH grant to fund the trial (Businesswire) - "Cancer Targeted Technology...announced today that it has started treating patients with advanced stage prostate cancer with its radiotherapeutic drug, CTT1403, in a Phase I clinical trial....the NIH announced that it was awarding CTT a competitive Small Business Innovation Research (SBIR) Phase IIB grant for ~$3.2M (over 3 years) to help fund the clinical trial and further the development of CTT1403."

Clinical • Trial status

Newly added product (Businesswire) - P1, Prostate cancer

Pipeline update